Trust Co. of Toledo NA OH increased its position in shares of Merck & Company, Inc. (NYSE:MRK) by 4.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 78,292 shares of the company’s stock after buying an additional 3,555 shares during the period. Merck & accounts for approximately 1.3% of Trust Co. of Toledo NA OH’s holdings, making the stock its 16th biggest position. Trust Co. of Toledo NA OH’s holdings in Merck & were worth $5,018,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vigilant Capital Management LLC boosted its holdings in shares of Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after buying an additional 250 shares during the period. Harbour Capital Advisors LLC acquired a new position in Merck & during the 1st quarter valued at $127,000. Pinnacle Bank acquired a new position in Merck & during the 1st quarter valued at $152,000. Dillon & Associates Inc. acquired a new position in Merck & during the 1st quarter valued at $206,000. Finally, Addison Capital Co acquired a new position in Merck & during the 1st quarter valued at $218,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Shares of Merck & Company, Inc. (NYSE MRK) traded down 0.40% during midday trading on Friday, reaching $64.03. 11,449,603 shares of the company’s stock were exchanged. The company’s 50 day moving average is $63.52 and its 200-day moving average is $63.68. Merck & Company, Inc. has a 12 month low of $58.29 and a 12 month high of $66.80. The stock has a market cap of $174.63 billion, a PE ratio of 34.67 and a beta of 0.81.

Merck & (NYSE:MRK) last released its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The company had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.93 earnings per share. Equities analysts forecast that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.94%. The ex-dividend date is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is currently 76.11%.

Several equities analysts recently commented on the stock. Credit Suisse Group set a $72.00 target price on shares of Merck & and gave the company a “buy” rating in a research note on Tuesday, June 6th. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BMO Capital Markets reiterated a “buy” rating and set a $72.00 target price on shares of Merck & in a research note on Friday, September 8th. Cowen and Company reiterated a “hold” rating and set a $70.00 target price on shares of Merck & in a research note on Friday, September 1st. Finally, UBS AG upped their target price on shares of Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, July 31st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. Merck & currently has an average rating of “Hold” and an average target price of $70.00.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/30/merck-company-inc-mrk-position-increased-by-trust-co-of-toledo-na-oh.html.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.